TW202229560A

TW202229560A - 治療法布瑞氏症之組成物及方法

治療法布瑞氏症之組成物及方法 Download PDF

Info

Publication number: TW202229560A
Authority: TW; Taiwan
Prior art keywords: hgla; gla; seq; sequence; aavhu68
Prior art date: 2020-10-09

Application number

TW110137528A

Other languages

English (en)

Chinese (zh)

Inventor

茱麗葉豪杜司

Original Assignee

賓州大學委員會

Priority date

2020-10-09

Filing date

2021-10-08

Publication date

2022-08-01

2021-10-08 Application filed by 賓州大學委員會 filed Critical 賓州大學委員會

2022-08-01 Publication of TW202229560A publication Critical patent/TW202229560A/zh

Links

238000000034 method Methods 0.000 title claims abstract description 106
239000000203 mixture Substances 0.000 title claims abstract description 93
208000024720 Fabry Disease Diseases 0.000 title claims abstract description 59
238000011282 treatment Methods 0.000 title claims abstract description 37
101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 claims abstract description 273
102000043404 human GLA Human genes 0.000 claims abstract description 268
230000014509 gene expression Effects 0.000 claims abstract description 185
239000013598 vector Substances 0.000 claims abstract description 166
108091026890 Coding region Proteins 0.000 claims abstract description 71
230000001105 regulatory effect Effects 0.000 claims abstract description 37
108090000623 proteins and genes Proteins 0.000 claims description 213
150000007523 nucleic acids Chemical group 0.000 claims description 109
210000000234 capsid Anatomy 0.000 claims description 98
235000001014 amino acid Nutrition 0.000 claims description 87
150000001413 amino acids Chemical class 0.000 claims description 75
210000004027 cell Anatomy 0.000 claims description 68
108091028043 Nucleic acid sequence Proteins 0.000 claims description 62
210000001519 tissue Anatomy 0.000 claims description 53
108090000765 processed proteins & peptides Proteins 0.000 claims description 50
239000002773 nucleotide Substances 0.000 claims description 45
125000003729 nucleotide group Chemical group 0.000 claims description 45
108091070501 miRNA Proteins 0.000 claims description 36
210000002706 plastid Anatomy 0.000 claims description 33
239000002679 microRNA Substances 0.000 claims description 32
239000008194 pharmaceutical composition Substances 0.000 claims description 30
241000282414 Homo sapiens Species 0.000 claims description 27
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 20
239000013603 viral vector Substances 0.000 claims description 20
239000002245 particle Substances 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 16
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
230000001124 posttranscriptional effect Effects 0.000 claims description 11
241001492404 Woodchuck hepatitis virus Species 0.000 claims description 10
238000009472 formulation Methods 0.000 claims description 10
230000007812 deficiency Effects 0.000 claims description 9
241000701161 unidentified adenovirus Species 0.000 claims description 9
102100026277 Alpha-galactosidase A Human genes 0.000 claims description 6
125000000539 amino acid group Chemical group 0.000 claims description 6
150000002632 lipids Chemical class 0.000 claims description 6
241000713666 Lentivirus Species 0.000 claims description 5
108091061960 Naked DNA Proteins 0.000 claims description 5
229920000642 polymer Polymers 0.000 claims description 5
241000125945 Protoparvovirus Species 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
229920001661 Chitosan Polymers 0.000 claims description 2
239000010954 inorganic particle Substances 0.000 claims description 2
208000013829 diffuse lymphatic malformation Diseases 0.000 claims 3
241001430294 unidentified retrovirus Species 0.000 claims 2
241000702421 Dependoparvovirus Species 0.000 abstract description 30
108091033319 polynucleotide Proteins 0.000 abstract description 2
102000040430 polynucleotide Human genes 0.000 abstract description 2
239000002157 polynucleotide Substances 0.000 abstract description 2
241000699670 Mus sp. Species 0.000 description 238
101150014526 Gla gene Proteins 0.000 description 204
235000018102 proteins Nutrition 0.000 description 128
102000004169 proteins and genes Human genes 0.000 description 128
230000000694 effects Effects 0.000 description 97
108700019146 Transgenes Proteins 0.000 description 93
102000005840 alpha-Galactosidase Human genes 0.000 description 86
108010030291 alpha-Galactosidase Proteins 0.000 description 86
230000035508 accumulation Effects 0.000 description 79
238000009825 accumulation Methods 0.000 description 79
229940024606 amino acid Drugs 0.000 description 72
238000001990 intravenous administration Methods 0.000 description 69
239000000047 product Substances 0.000 description 64
125000003275 alpha amino acid group Chemical group 0.000 description 55
210000003734 kidney Anatomy 0.000 description 53
210000003594 spinal ganglia Anatomy 0.000 description 51
210000002216 heart Anatomy 0.000 description 49
210000002966 serum Anatomy 0.000 description 47
241001465754 Metazoa Species 0.000 description 43
238000011887 Necropsy Methods 0.000 description 42
239000003981 vehicle Substances 0.000 description 41
210000002381 plasma Anatomy 0.000 description 38
210000004185 liver Anatomy 0.000 description 36
238000012384 transportation and delivery Methods 0.000 description 33
108090000565 Capsid Proteins Proteins 0.000 description 32
102100023321 Ceruloplasmin Human genes 0.000 description 32
108020004705 Codon Proteins 0.000 description 31
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 30
239000002953 phosphate buffered saline Substances 0.000 description 30
210000004369 blood Anatomy 0.000 description 29
239000008280 blood Substances 0.000 description 29
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 28
108020004414 DNA Proteins 0.000 description 27
208000024891 symptom Diseases 0.000 description 27
-1 idose Amino acids Chemical class 0.000 description 26
238000003364 immunohistochemistry Methods 0.000 description 26
239000003623 enhancer Substances 0.000 description 25
239000002609 medium Substances 0.000 description 25
235000003704 aspartic acid Nutrition 0.000 description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
108091029500 miR-183 stem-loop Proteins 0.000 description 24
230000000295 complement effect Effects 0.000 description 23
230000001965 increasing effect Effects 0.000 description 23
238000004458 analytical method Methods 0.000 description 22
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 22
201000010099 disease Diseases 0.000 description 22
230000002255 enzymatic effect Effects 0.000 description 22
108020004707 nucleic acids Proteins 0.000 description 22
102000039446 nucleic acids Human genes 0.000 description 22
210000002700 urine Anatomy 0.000 description 22
239000013607 AAV vector Substances 0.000 description 21
101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 21
102000004196 processed proteins & peptides Human genes 0.000 description 20
238000011002 quantification Methods 0.000 description 19
102000004190 Enzymes Human genes 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
239000012634 fragment Substances 0.000 description 18
108020004999 messenger RNA Proteins 0.000 description 18
108091023796 miR-182 stem-loop Proteins 0.000 description 18
230000004048 modification Effects 0.000 description 18
238000012986 modification Methods 0.000 description 18
241000700605 Viruses Species 0.000 description 17
230000000747 cardiac effect Effects 0.000 description 17
230000006240 deamidation Effects 0.000 description 17
238000002347 injection Methods 0.000 description 17
239000007924 injection Substances 0.000 description 17
GRGNVOCPFLXGDQ-TWHXEDJUSA-N (2r,3r,4s,5r,6r)-2-[(2r,3r,4r,5r,6s)-6-[(2r,3s,4r,5r,6r)-6-[(e,2s,3r)-2-amino-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 GRGNVOCPFLXGDQ-TWHXEDJUSA-N 0.000 description 16
230000037396 body weight Effects 0.000 description 16
210000004556 brain Anatomy 0.000 description 16
238000001415 gene therapy Methods 0.000 description 16
239000000523 sample Substances 0.000 description 16
238000012360 testing method Methods 0.000 description 16
230000003612 virological effect Effects 0.000 description 16
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 15
210000000056 organ Anatomy 0.000 description 15
241000702423 Adeno-associated virus - 2 Species 0.000 description 14
239000000090 biomarker Substances 0.000 description 14
210000001175 cerebrospinal fluid Anatomy 0.000 description 14
230000006870 function Effects 0.000 description 14
238000007913 intrathecal administration Methods 0.000 description 14
230000009467 reduction Effects 0.000 description 14
230000010076 replication Effects 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 13
108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 13
239000002253 acid Substances 0.000 description 13
239000000872 buffer Substances 0.000 description 13
231100000673 dose–response relationship Toxicity 0.000 description 13
238000011156 evaluation Methods 0.000 description 13
210000005003 heart tissue Anatomy 0.000 description 13
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
230000003472 neutralizing effect Effects 0.000 description 12
229920001184 polypeptide Polymers 0.000 description 12
238000003860 storage Methods 0.000 description 12
238000006467 substitution reaction Methods 0.000 description 12
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
108010074328 Interferon-gamma Proteins 0.000 description 11
241000283973 Oryctolagus cuniculus Species 0.000 description 11
230000009615 deamination Effects 0.000 description 11
238000006481 deamination reaction Methods 0.000 description 11
239000004220 glutamic acid Substances 0.000 description 11
238000010172 mouse model Methods 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
239000000758 substrate Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
230000009261 transgenic effect Effects 0.000 description 11
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
230000005867 T cell response Effects 0.000 description 10
238000004422 calculation algorithm Methods 0.000 description 10
238000002641 enzyme replacement therapy Methods 0.000 description 10
230000006872 improvement Effects 0.000 description 10
238000007901 in situ hybridization Methods 0.000 description 10
230000035772 mutation Effects 0.000 description 10
210000002569 neuron Anatomy 0.000 description 10
230000004044 response Effects 0.000 description 10
208000036632 Brain mass Diseases 0.000 description 9
101710163270 Nuclease Proteins 0.000 description 9
230000015271 coagulation Effects 0.000 description 9
238000005345 coagulation Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 9
230000008595 infiltration Effects 0.000 description 9
238000001764 infiltration Methods 0.000 description 9
230000003907 kidney function Effects 0.000 description 9
210000000278 spinal cord Anatomy 0.000 description 9
239000000126 substance Substances 0.000 description 9
238000010361 transduction Methods 0.000 description 9
230000026683 transduction Effects 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
210000004413 cardiac myocyte Anatomy 0.000 description 8
235000013922 glutamic acid Nutrition 0.000 description 8
210000000265 leukocyte Anatomy 0.000 description 8
238000004806 packaging method and process Methods 0.000 description 8
125000006850 spacer group Chemical group 0.000 description 8
239000004094 surface-active agent Substances 0.000 description 8
FOWNDZJYGGTHRO-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-aminobutanedioic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC(O)=O FOWNDZJYGGTHRO-DKWTVANSSA-N 0.000 description 7
239000004471 Glycine Substances 0.000 description 7
108091092195 Intron Proteins 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
102000013394 Troponin I Human genes 0.000 description 7
108010065729 Troponin I Proteins 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
229960002449 glycine Drugs 0.000 description 7
150000002500 ions Chemical class 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
238000004949 mass spectrometry Methods 0.000 description 7
230000004770 neurodegeneration Effects 0.000 description 7
210000005084 renal tissue Anatomy 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
108010082126 Alanine transaminase Proteins 0.000 description 6
108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
206010003591 Ataxia Diseases 0.000 description 6
108010067770 Endopeptidase K Proteins 0.000 description 6
102000006395 Globulins Human genes 0.000 description 6
108010044091 Globulins Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
102100037850 Interferon gamma Human genes 0.000 description 6
241000282567 Macaca fascicularis Species 0.000 description 6
238000003556 assay Methods 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
230000008488 polyadenylation Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000013608 rAAV vector Substances 0.000 description 6
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
229960004295 valine Drugs 0.000 description 6
239000004474 valine Substances 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
108020005345 3' Untranslated Regions Proteins 0.000 description 5
102000008070 Interferon-gamma Human genes 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
206010028851 Necrosis Diseases 0.000 description 5
108700026244 Open Reading Frames Proteins 0.000 description 5
206010040030 Sensory loss Diseases 0.000 description 5
238000008050 Total Bilirubin Reagent Methods 0.000 description 5
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
150000001510 aspartic acids Chemical class 0.000 description 5
230000007845 axonopathy Effects 0.000 description 5
108010006025 bovine growth hormone Proteins 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000002950 deficient Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000013461 design Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 5
239000012537 formulation buffer Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
229940027941 immunoglobulin g Drugs 0.000 description 5
238000011532 immunohistochemical staining Methods 0.000 description 5
229960003130 interferon gamma Drugs 0.000 description 5
230000003902 lesion Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
230000002132 lysosomal effect Effects 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000017074 necrotic cell death Effects 0.000 description 5
230000000717 retained effect Effects 0.000 description 5
230000001953 sensory effect Effects 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
238000010186 staining Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
210000005239 tubule Anatomy 0.000 description 5
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
108020003589 5' Untranslated Regions Proteins 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
102000006734 Beta-Globulins Human genes 0.000 description 4
108010087504 Beta-Globulins Proteins 0.000 description 4
108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
102000001554 Hemoglobins Human genes 0.000 description 4
102000004157 Hydrolases Human genes 0.000 description 4
108090000604 Hydrolases Proteins 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
108091093037 Peptide nucleic acid Proteins 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 4
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000033558 biomineral tissue development Effects 0.000 description 4
238000004820 blood count Methods 0.000 description 4
210000005013 brain tissue Anatomy 0.000 description 4
239000007975 buffered saline Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000004590 computer program Methods 0.000 description 4
238000012937 correction Methods 0.000 description 4
230000007850 degeneration Effects 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
238000003306 harvesting Methods 0.000 description 4
208000006454 hepatitis Diseases 0.000 description 4
231100000283 hepatitis Toxicity 0.000 description 4
210000005260 human cell Anatomy 0.000 description 4
230000002055 immunohistochemical effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
238000000185 intracerebroventricular administration Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
201000006370 kidney failure Diseases 0.000 description 4
230000004807 localization Effects 0.000 description 4
LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 description 4
229950007469 migalastat Drugs 0.000 description 4
238000005457 optimization Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
229920001993 poloxamer 188 Polymers 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
238000009163 protein therapy Methods 0.000 description 4
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
238000003753 real-time PCR Methods 0.000 description 4
210000001044 sensory neuron Anatomy 0.000 description 4
229960002930 sirolimus Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
231100000041 toxicology testing Toxicity 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000013519 translation Methods 0.000 description 4
210000002845 virion Anatomy 0.000 description 4
241001164825 Adeno-associated virus - 8 Species 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108020004206 Gamma-glutamyltransferase Proteins 0.000 description 3
240000005926 Hamelia patens Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
238000011529 RT qPCR Methods 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
101150110932 US19 gene Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
125000003368 amide group Chemical group 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
238000011888 autopsy Methods 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
210000003703 cisterna magna Anatomy 0.000 description 3
230000024203 complement activation Effects 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000011304 droplet digital PCR Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
230000005713 exacerbation Effects 0.000 description 3
230000029142 excretion Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000013467 fragmentation Methods 0.000 description 3
238000006062 fragmentation reaction Methods 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
239000003547 immunosorbent Substances 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
210000002429 large intestine Anatomy 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
210000001617 median nerve Anatomy 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
201000008383 nephritis Diseases 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
238000010984 neurological examination Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
210000000557 podocyte Anatomy 0.000 description 3
229920001983 poloxamer Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
229960001153 serine Drugs 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
241000894007 species Species 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229960002898 threonine Drugs 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000035899 viability Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
239000003643 water by type Substances 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
241001655883 Adeno-associated virus - 1 Species 0.000 description 2
241000202702 Adeno-associated virus - 3 Species 0.000 description 2
241001164823 Adeno-associated virus - 7 Species 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000034309 Bacterial disease carrier Diseases 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
241000124740 Bocaparvovirus Species 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
206010048610 Cardiotoxicity Diseases 0.000 description 2
108090000317 Chymotrypsin Proteins 0.000 description 2
108700010070 Codon Usage Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010015548 Euthanasia Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
101000802640 Homo sapiens Lactosylceramide 4-alpha-galactosyltransferase Proteins 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
208000008017 Hypohidrosis Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010056677 Nerve degeneration Diseases 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
108010049936 agalsidase alfa Proteins 0.000 description 2
108010056760 agalsidase beta Proteins 0.000 description 2
229960003767 alanine Drugs 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
102000013529 alpha-Fetoproteins Human genes 0.000 description 2
108010026331 alpha-Fetoproteins Proteins 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
229940125715 antihistaminic agent Drugs 0.000 description 2
239000000739 antihistaminic agent Substances 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
231100000259 cardiotoxicity Toxicity 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
229960002376 chymotrypsin Drugs 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000003205 diastolic effect Effects 0.000 description 2
239000013024 dilution buffer Substances 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
238000002592 echocardiography Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
229940014516 fabrazyme Drugs 0.000 description 2
239000000835 fiber Substances 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000004217 heart function Effects 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
238000007625 higher-energy collisional dissociation Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
238000005304 joining Methods 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
229960003136 leucine Drugs 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
238000009593 lumbar puncture Methods 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000034217 membrane fusion Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
238000001823 molecular biology technique Methods 0.000 description 2
238000002887 multiple sequence alignment Methods 0.000 description 2
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
229960004866 mycophenolate mofetil Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229940044519 poloxamer 188 Drugs 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
210000001938 protoplast Anatomy 0.000 description 2
101150066583 rep gene Proteins 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000037152 sensory function Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000011232 storage material Substances 0.000 description 2
210000002330 subarachnoid space Anatomy 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
238000004885 tandem mass spectrometry Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
241000580270 Adeno-associated virus - 4 Species 0.000 description 1
241001634120 Adeno-associated virus - 5 Species 0.000 description 1
241000972680 Adeno-associated virus - 6 Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101710099283 Alpha-galactosidase A Proteins 0.000 description 1
241000024188 Andala Species 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
108091005658 Basic proteases Proteins 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
241000589562 Brucella Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
241000739046 Cervine adenovirus Species 0.000 description 1
102100039501 Chymotrypsinogen B Human genes 0.000 description 1
101710178550 Chymotrypsinogen B2 Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
239000003154 D dimer Substances 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010046992 Galactosylgalactosylglucosylceramidase Proteins 0.000 description 1
101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
102100030479 Germinal center-associated signaling and motility protein Human genes 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 description 1
101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 1
101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 description 1
101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
101150031639 IV gene Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000000521 Immunophilins Human genes 0.000 description 1
108010016648 Immunophilins Proteins 0.000 description 1
206010051792 Infusion related reaction Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000003810 Interleukin-18 Human genes 0.000 description 1
108090000171 Interleukin-18 Proteins 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102100035838 Lactosylceramide 4-alpha-galactosyltransferase Human genes 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
206010024214 Lenticular opacities Diseases 0.000 description 1
208000033868 Lysosomal disease Diseases 0.000 description 1
208000015439 Lysosomal storage disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
108700011259 MicroRNAs Proteins 0.000 description 1
208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000013324 OneBac system Methods 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
241000364051 Pima Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
241001506137 Rapa Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038540 Renal tubular necrosis Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010032838 Sialoglycoproteins Proteins 0.000 description 1
102000007365 Sialoglycoproteins Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
241000283925 Spermophilus Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
102000017299 Synapsin-1 Human genes 0.000 description 1
108050005241 Synapsin-1 Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
101150114976 US21 gene Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
241000283929 Urocitellus parryii Species 0.000 description 1
108091034131 VA RNA Proteins 0.000 description 1
101150004676 VGF gene Proteins 0.000 description 1
206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
101710086987 X protein Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
229930183665 actinomycin Natural products 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229960001239 agalsidase alfa Drugs 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
201000009431 angiokeratoma Diseases 0.000 description 1
206010002512 anhidrosis Diseases 0.000 description 1
230000037001 anhydrosis Effects 0.000 description 1
238000000137 annealing Methods 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
239000003972 antineoplastic antibiotic Substances 0.000 description 1
229940045985 antineoplastic platinum compound Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000007623 carbamidomethylation reaction Methods 0.000 description 1
230000037198 cardiovascular physiology Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000011072 cell harvest Methods 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000002038 chemiluminescence detection Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000562 conjugate Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000011262 co‐therapy Methods 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
229940099500 cystamine Drugs 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000007847 digital PCR Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000011833 dog model Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229940073018 elliotts b Drugs 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000003028 enzyme activity measurement method Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229940073505 ethyl vanillin Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000208 fibrin degradation product Substances 0.000 description 1
108010052295 fibrin fragment D Proteins 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000005021 gait Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000003904 glomerular cell Anatomy 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002307 glutamic acids Chemical class 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
210000002837 heart atrium Anatomy 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003361 heart septum Anatomy 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
108700025184 hepatitis B virus X Proteins 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
102000051631 human SERPINA1 Human genes 0.000 description 1
102000048799 human SERPINA7 Human genes 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229940072106 hydroxystearate Drugs 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
208000022119 inability to concentrate Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
229960004359 iodixanol Drugs 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000002122 magnetic nanoparticle Substances 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006996 mental state Effects 0.000 description 1
229960003151 mercaptamine Drugs 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
208000005907 mitral valve insufficiency Diseases 0.000 description 1
238000009126 molecular therapy Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
238000011201 multiple comparisons test Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008035 nerve activity Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000012510 peptide mapping method Methods 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
150000003058 platinum compounds Chemical class 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000575 polymersome Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000036544 posture Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000009023 proprioceptive sensation Effects 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
108010053400 protease Ci Proteins 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000026447 protein localization Effects 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
210000000449 purkinje cell Anatomy 0.000 description 1
238000010833 quantitative mass spectrometry Methods 0.000 description 1
238000004725 rapid separation liquid chromatography Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
239000010979 ruby Substances 0.000 description 1
229910001750 ruby Inorganic materials 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000004904 shortening Methods 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229960005480 sodium caprylate Drugs 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002311 subsequent effect Effects 0.000 description 1
229940044609 sulfur dioxide Drugs 0.000 description 1
235000010269 sulphur dioxide Nutrition 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229920000428 triblock copolymer Polymers 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
230000010415 tropism Effects 0.000 description 1
210000004926 tubular epithelial cell Anatomy 0.000 description 1
238000004704 ultra performance liquid chromatography Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1